Flockscreen LAMP Avian Influenza Test for Poultry First Rapid Molecular Test to Accurately Detect the Presence of Virus in Both Cloacal and Oropharyngeal Samples

Alveo Technologies developed this groundbreaking product in partnership with x-Ovo, Royal GD and Pharmsure; first shipments of Flockscreen to EMEA expected Q3 2024

ALAMEDA, Calif., June 27, 2024 /PRNewswire/ -- Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary technology platform, today announced that rigorous development and testing has demonstrated that the Flockscreen LAMP Avian Influenza Molecular Test can accurately detect the presence of virus in both cloacal and oropharyngeal samples from poultry with comparable limit of detection, sensitivity and specificity. Alveo and their development partners performed more than 20,000 reactions on over 4000 assay cartridges during their evaluation of over 100 candidate primer sets and assay conditions, using both contrived and clinical samples. Relevant regulatory bodies have been engaged and appropriate validation and verification activities will be completed prior to shipment.

The product is available today for pre-sale in Europe and the Middle East. The company expects to begin shipping in volume in the third quarter of 2024.

The current HPAI panzootic has recently spread to cattle and at least 47 other mammalian species. Due to current disease control legislation, this has led to the destruction of more than half a billion poultry worldwide. Rapid, accurate tests are vital for early detection and containment, protection of the poultry industry, the prevention of zoonotic transmission and spillover events from one species to another, food security, the maintenance of agricultural trade, and ongoing monitoring and surveillance.

Current agricultural tests for highly pathogenic avian influenza (HPAI) all suffer from one of several significant drawbacks that make them unsuited to these use cases. Polymerase chain reaction (PCR) requires lab processing, which means it can take days to receive a result, and vaccination causes serology tests to turn positive even if the bird is not infected¹. Lateral flow (also known as antigen or instant tests) lacks sensitivity and produces a significant percentage of false negative results.

Alveo's portable and rugged molecular diagnostic platform has been designed to provide accurate, rapid test results at the point of need. It functions as a core component of a notifiable disease electronic management ecosystem that the company and its strategic partners have developed to support producers, as well as governmental bodies who are looking to expand the surveillance of important zoonotic pathogens. Two multiplexed panels enable the on-site broad detection of Avian Influenza Type A virus (targeting matrix gene) in poultry with differentiation of H5, H7, and H9 subtypes using oropharyngeal or cloacal samples. Both panels contain 7 assays, 6 of which are identical between cartridges. This configuration ensures the greatest coverage of the most clinically relevant global AI strains from the past 5-10 years, through to the current strains. The platform's rugged design enables it to function in the field under extreme conditions, including very hot and near freezing temperatures, following a drop of one meter, and when subjected to movement and vibration, which are common challenges encountered in field settings. 

Alveo has developed assays for Flockscreen LAMP AI on its proprietary molecular platform with several partners —including x-OvO, Royal GD, and Pharmsure International Ltd. — and it will provide healthcare and government authorities with a rapid, decentralized, molecular test that eliminates the need to ship hazardous samples to a lab. Additionally, the platform has the capability to wirelessly upload time-stamped geotagged results to a common portal, providing organizations with near real-time information on the spread of the virus. The platform will provide veterinarians with intuitive, rapid, point-of-need testing. For producers, Flockscreen will empower rapid responses to reduce the disease's spread and mitigate the impact on their business.

"The creation of a decentralized testing ecosystem that respects and expands process control by disease management authorities, combined with molecular biology levels of accuracy, could lead a paradigm shift in the way notifiable disease challenges are controlled," said Dr. Richard Currie, President, x-OvO.

"Alveo's molecular diagnostic platform is a groundbreaking technology that raises the bar for speed and accuracy in point-of-need diagnostic testing," said Wim Kieftenbeld, Director Business Development at Royal GD. "Combined with our expertise in veterinary diseases and diagnostics, we've worked together to develop an assay that accurately and rapidly delivers results at point of need for both cloacal and oropharyngeal samples, a first for agricultural diagnostics for HPAI."

"Our platform makes it simple to test for HPAI in poultry, and we will be the first diagnostic of its kind that can test both cloacal and oropharyngeal samples," said Shaun Holt, CEO at Alveo. "Our rugged design enables healthcare providers, veterinarians, growers, and public health officials to obtain rapid results at point of need so they can take immediate action."

Alveo expects first customer shipments of Flockscreen LAMP AI in EMEA to begin by Q3 2024. For more information visit: alveotechnologies.com/flockscreen

About Alveo 
Alveo is the first company to make molecular detection and diagnostics universally accessible – on the farm, in the field, in the clinic, or in the manufacturing plant – helping prevent or significantly limit the destructive impact of viruses, fungi, bacteria, and other pathogens by detecting earlier at the Point of Need™. Alveo's rugged and portable, multiplex-capable diagnostic platform employs a patented method of direct electrical sensing of nucleic acid amplification to provide affordable, rapid, and accurate results. By enabling early pathogen detection, Alveo helps manage global health, food security, and supply chain resiliency by providing actionable insights at lightspeed. Know Sooner, Act Faster™ with Alveo. For more, visit: https://www.alveotechnologies.com/.

¹ Tumpey TM, Alvarez R, Swayne DE, Suarez DL. Diagnostic approach for differentiating infected from vaccinated poultry on the basis of antibodies to NS1, the nonstructural protein of influenza A virus. J Clin Microbiol. 2005 Feb;43(2):676-83. doi: 10.1128/JCM.43.2.676-683.2005. PMID: 15695663; PMCID: PMC548100.

Media contact
Jeff Miller
[email protected]
541-207-6413

SOURCE Alveo Technologies